Cooper Ronald Harold Wilfred 4

What Happened
Cooper Ronald Harold Wilfred (listed as Ronald Cooper), a director of C4 Therapeutics, received a grant of 62,000 derivative securities (reported as an award) on June 24, 2026. The transaction is reported at $0.00 per share (total reported value $0), indicating a grant of options/awarded derivative instruments rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-24; Form 4 filed: 2026-06-26 (appears timely within the usual 2-business-day window).
• Quantity: 62,000 derivative securities (award/option). Reported price: $0.00; reported value: $0.
• Shares owned after the transaction: not specified in this filing.
• Footnote: The option vests and becomes exercisable in full upon the earlier of (i) June 24, 2027 and (ii) the next annual meeting of stockholders, subject to the recipient’s continued service as a board member.
• No indication of immediate exercise, sale, tax‑withholding, or a 10b5‑1 plan in this filing.

Context
This filing documents a board compensation award (an option/derivative grant) rather than a market purchase or sale. Such awards are common as director compensation and do not represent an immediate cash outlay or sale of stock — the economic value depends on future vesting and any exercise terms. The award vests only if the director remains in service through the stated vesting date or event.